Hormonal
Higher baseline levels of Myostatin are associated with significant functional decline (Gait Speed and 6MWD) in older adults with sarcopenia, while inflammatory markers (IL-6, hsCRP) show less consistent or no correlation with functional decline.
While not yet a standard clinical test, high Myostatin levels may predict functional decline in sarcopenic older adults. In contrast, common inflammatory markers (CRP, IL-6) did not correlate with functional decline in this study, suggesting they may not be the primary drivers of functional loss in this population.
when the median of Myostatin blood level (2651.55 pg/mL) was used to determine the two subgroups, we observed that the group of patients with a “high” level of myostatin (> 2651.55 pg/L) had a significant reduction in the GS/400MWT change from baseline to Month 6/EOS of -0.05 ± 0.208 m/s (p = 0.044)... No correlation was shown with 400MWT and no correlation was observed for both assessments with IL-6
Why this rating
Exploratory analysis with nominal p-values and no correction for multiplicity; small sample size for biomarker subgroups.
Source
Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS)
Roger A. Fielding et al. · BMC Geriatrics · 2025
DOI 10.1186/s12877-025-05895-9
More from this paper
- In older adults with sarcopenia, those with higher baseline functional reserve (Gait Speed ≥ 0.8 m/s or SPPB = 8) experience significant functional decline over 6 months, whereas those with lower baseline function do not show significant change in gait speed.Moderate
- Sarcopenic Obesity (SO) is associated with significant deterioration in functional exercise capacity (6MWD) over 6 months, even when gait speed changes are not statistically significant.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →